Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Breast Cancer, Lung Cancer, Pancreas Can...
Phase PHASE2
Enrollment 34
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The primary objective of this single arm, open label, phase II trial is to determine if axelopran use impacts cancer control in patients with advanced cancers of the lung, breast, pancreas, and prostate. The primary study period for assessing the primary aim is through day 43 (6 weeks). The main questions it aims to answer are: * Does axelopran show a signal for efficacy in slowing tumor progression? * Is axelopran safe and tolerable for long-term use in this patient population? * Does axelopran show a signal for efficacy in improving bowel function and quality of life? * Does axelopran show a signal for efficacy in reducing systemic inflammation, cachexia, and prognostic serum biomarkers of inflammation? Patients will take axelopran as monotherapy after relapse or progression on or after standard systemic therapy. Clinician and patient must be willing to attempt a delay in next line of systemic cancer therapy (if available) until day 43 to assess change in cancer status on repeat imaging. Clinician can move to the next line of therapy whenever deemed clinically necessary. Participants will: * take oral axelopran capsules daily for up to 1 year, or longer if deriving benefit * attend 10 in-person study visits, each lasting approximately 1-2 hours * complete study procedures including but not limited to imaging exams, blood draws, electronic health surveys, and physical assessments

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: axelopran — axelopran capsules

Primary Outcomes

  • Objective response rate (including complete response and partial response) (43 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-04-27
Completion: 2028-11-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 34 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: HealthPartners Institute
Collaborators: Glycyx MOR Inc.
Principal Investigators:
  • Dylan Zylla, MD, MS (PRINCIPAL_INVESTIGATOR) - HealthPartners Institute Cancer Research Center
Contact Information
Study Contact:
Jordan Cowger, MPH
952-993-6071
jordan.cowger@parknicollet.com
Alissa Gavenda, RN
952-993-6705
alissa.gavenda@parknicollet.com
HealthPartners Frauenshuh Cancer Research Center
Lisa Wahowske, RN
651-254-1517
lisa.wahowske@parknicollet.com
HealthPartners Cancer Center at Regions Hospital
Interventions
  • Drug: axelopran — axelopran capsules
Study Locations (2 sites)
HealthPartners Frauenshuh Cancer Research Center, Saint Louis Park, Minnesota 55426 United States
HealthPartners Cancer Center at Regions Hospital, Saint Paul, Minnesota 55101 United States
Eligibility Criteria
Inclusion Criteria: 1. Adults (aged 18 or more at enrollment). 2. Histologically or cytologically proven cancer of the prostate (carcinoma), breast (carcinoma), pancreas (carcinoma), and lung (non-small cell lung carcinoma (NSCLC)) that has relapsed or progressed on or after a standard systemic treatment that has included cytotoxic chemotherapy. 3. Advanced stage (locally advanced or metastatic) with no definitive plans for curative-intent therapy. 4. A minimum life expectancy of at least 2 months at the time of the screening visit. 5. Current use of an opioid medication with an average of 5mg OME/day over the past 3 days. 6. At least one measurable lesion meeting RECIST v1.1 criteria. 7. At least 2 weeks since last cancer-directed therapy: 1. NSCLC and pancreatic cancer must have received at least one line of systemic cytotoxic chemotherapy (+/- immune checkpoint inhibitor) in the locally advanced/metastatic setting. 2. Breast cancer must be considered refractory to hormone therapy (i.e., progressed on standard estrogen blocking therapy) or hormone negative (i.e., estrogen and progesterone-receptor negative) and have received at least one line of systemic cytotoxic chemotherapy in the locally advanced/metastatic setting. 3. Prostate cancer must be considered metastatic castrate-resistant prostate cancer (mCRPC) and have progressed on at least one androgen receptor pathway inhibitor (ARPI) and docetaxel. Docetaxel could be given in the metastatic castrate-sensitive setting, and/or later in the mCRPC setting. Baseline testosterone level must be \<50 ng/dL and surgical or ongoing medical castration must be maintained throughout the duration of the study. 8. Patients must a) have relapsed or progressed on or after all standard therapy, b) be intolerant to standard therapy, c) not have standard therapy available that confers a significant clinical benefit, d) decline other standard therapy or agree with treating oncologist that a period of active surveillance off therapy is reasonable. 9. Clinician and patient are willing to attempt a delay in next line of systemic cancer therapy (if available) until day 43 to assess change in cancer status on repeat imaging. Clinician can move to next line of therapy at any time if a patient's clinical course changes and urgent new treatment is required. Patients will be allowed to remain on axelopran if that occurs. a) Planned palliative radiation therapy should be completed prior to study enrollment. Palliative radiation done during the primary study period would be considered next line of cancer therapy. 10. Must be willing to report baseline and required patient-reported outcomes and report daily bowel movement frequency for monitoring stool changes. 11. For a female subject of childbearing potential, must have documentation of a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day 1. All women are considered to be of childbearing potential unless they are postmenopausal (amenorrheic for at least 2 years) or documented to be surgically sterile (bilateral tubal ligation or hysterectomy). 12. Sexually active subjects must use a highly effective method of contraception during the study and for at least 90 days after completion of study drug dosing. 1. A highly effective method of birth control is defined as one that results in a low failure rate (i.e., \< 1% per year) when used consistently and correctly, such as condom + diaphragm, condom + spermicide, diaphragm + spermicide, or intrauterine device (IUD) with documented failure rate of \< 1% per year, or oral/injectable/implanted hormonal contraceptives used in combination with an additional barrier method. 2. Males should refrain from donating sperm during the study and for 90 days after completion of study drug. Exclusion Criteria: 1. Any previous gastrointestinal surgery, except uncomplicated appendectomy or cholecystectomy. 2. Any of the included cancer cohorts where active malignancy causes direct extension/invasion of the GI tract from local spread or distant metastasis. 3. Current, active, untreated brain metastases. 4. History of fecal incontinence/impaction; irritable bowel syndrome; inflammatory bowel disease; intestinal obstruction; GI or pelvic disorders known to affect bowel transit, produce GI obstruction, or contribute to bowel dysfunction; fecal impaction requiring medical intervention within 1 month of enrollment. 5. Subject is unable to eat, drink, take, or hold down oral medications. 6. Use of buprenorphine, alvimopan, naltrexone, methylnaltrexone, naloxone, lubiprostone, linaclotide, or tapentadol therapy within 14 days before enrollment and inability or unwillingness to discontinue use until the end of the study. 7. Receipt of strong inhibitors of CYP3A4 (e.g., antifungal azoles, grapefruit juice) or strong inducers of CYP3A4 (e.g., rifampin or carbamazepine), including any herbal medications such as St. John's Wort, within the last 14 days or 5 half-lives, whichever is longer, prior to study drug administration. 8. Receipt of inhibitors of p-glycoprotein (P-gp) within the last 14 days prior to study drug administration. 9. Receipt of anti-VEGF therapies (i.e. bevacizumab) within the last 30 days prior to study drug administration. 10. Subjects with clinically significant abnormal ECG at screening or before randomization in the opinion of the Investigator, or a QTc \> 470 msec (per Fridericia's correction). 11. Presence of unstable diseases, in the opinion of the Investigator, such as cardiovascular (e.g., acute myocardial infarction or acute coronary syndrome \< 3 month history), respiratory (e.g., requires oxygen), gastrointestinal (e.g., symptomatic diverticulitis, irritable bowel syndrome \[IBS\], etc.), endocrine (e.g., uncontrolled diabetes or A1c \> 10%), hematologic, neurologic, psychiatric (e.g., schizophrenia, unstable anxiety disorder, acute psychosis, depression with suicidal ideation, etc.), or any other significant conditions that may affect subject assessment. 12. Any other condition which, in the opinion of the investigator, could confound or interfere with evaluation of safety, efficacy, or tolerability of the investigational drug, or prevent compliance with the study protocol. 13. Women who are pregnant, breastfeeding, or of childbearing potential without the use of birth control.
Conditions Glaucoma
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

To evaluate the efficacy and safety of istent inject W in reducing intraocular pressure in Chinese adult patients with open-angle glaucoma complicated with cataract.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Procedure: PHACO+PC-IOL+iStent — PHACO+PC-IOL+iStent
  • Procedure: PHACO+PC-IOL — PHACO+PC-IOL

Primary Outcomes

  • intraocular pressure (Baseline, 1 day, 1 week, 1 month, 3 months, 6 months and 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-07
Completion: 2027-10-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
Principal Investigators:
  • Kaijun Wang (STUDY_DIRECTOR) - Eye Center, the 2nd Affiliated Hospital, Medical College of Zhejiang Universit
Contact Information
Study Contact:
Kaijun wang, MD
+86 0571 87783759
wkj992@126.com
Kaijun Wang, MD
+86 0571 87783759
wkj992@126.com
Eye Center, the 2nd Affiliated Hospital, Medical College of Zhejiang University
Interventions
  • Procedure: PHACO+PC-IOL+iStent — PHACO+PC-IOL+iStent
  • Procedure: PHACO+PC-IOL — PHACO+PC-IOL
Study Locations (1 sites)
Eye Center, the 2nd Affiliated Hospital, Medical College of Zhejiang University, Hangzhou, China
Eligibility Criteria
Inclusion Criteria: * Gender is not limited. Applicants must be 18 years old or above; * Study patients whose eyes were diagnosed with open-angle glaucoma; * The study eye was diagnosed with cataract and met the conditions for phacoemulsification, with the best corrected visual acuity ≤0.7(patients with the best corrected visual acuity \>0.7 who were determined by the researcher to need cataract surgery could be enrolled); * Angular endoscopy confirmed that the opening Angle of the study eye was normal (defined as Shaffer grade ≥3, and there was no peripheral anterior iris adhesion, polycythemia or other abnormal conditions that might affect the correct placement of the stent); * The patient is capable and willing to provide written informed consent and participate in the regular postoperative follow-up as required. Exclusion Criteria: * Patients with angle-closure, pigmentary or pseudo-exfoliative glaucoma; * Patients with traumatic, malignant uveitis, neovascular or glaucoma related to vascular diseases; * Suffering from severe diabetic retinopathy, retinal detachment, central retinal vein or artery occlusion, retinal chromosomal degeneration, macular degeneration, macular edema, and determined by researchers to potentially affect surgical safety; * Patients with identifiable congenital abnormalities of the anterior chamber Angle; * Having clinically significant corneal dystrophy, active inflammation or having undergone surgery that may interfere with the reliability of intraocular pressure measurement; * Patients with retrobulbar tumors, thyroid eye disease, cavernous sinus fistula, Sturge-Weber syndrome or any other disease that may cause elevated venous pressure in the outer sclera; * Suffering from eye or systemic diseases that affect surgical safety or subsequent examinations; * Pregnant women, lactating women, women of childbearing age who plan to get pregnant during the research period or are unable to take effective contraceptive measures; * Failure to follow the doctor's advice; * Other circumstances where the researcher determines that the patient is not suitable for inclusion
Conditions Acute Asthma, Dexamethasone
Phase PHASE4
Enrollment 104
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Steroids given by mouth are an important first line treatment for children presenting with asthma attacks. Dexamethasone is the steroid used in some emergency departments (EDs) because of the need for a single dose and as it is well tolerated. The dose of dexamethasone in treating asthma attacks is not clearly established. This study compares two different doses of dexamethasone in children presenting with an asthma attack. Investigators will compare the effect of two different doses in reducing the need for a repeat prescription of steroids for an asthma attack in the 2 weeks after the first treatment. The investigators will also look at how often children attend the ED or their GP after being given treatment as well as the acceptability to parents and children. Although this study may provide an answer to the question of whether the different doses have the same effect, the investigators believe that a larger study will be needed to provide robust generalisable evidence, as well as to ensure that the outcomes are truly what matters to parents, children and healthcare professionals. This study will provide valuable information to enable a larger study to be undertaken.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: dexamethasone oral — The interventions are Dexamethasone, 0.3mg/kg versus 0.6 mg/kg

Primary Outcomes

  • Participant recruitment (7 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2026-02-23
Completion: 2026-08-31
Eligibility
Age: 4 Years and older
Sex: ALL
Volunteers: false
Enrollment: 104 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sheffield Children's NHS Foundation Trust
Principal Investigators:
  • Judith Gilchrist (PRINCIPAL_INVESTIGATOR) - Sheffield Children's NHS Foundation Trust
Contact Information
Study Contact:
Meena Balasubramanian
0114 3053136
meena.balasubramanian@nhs.net
Gillian Gatenby
0114 3053136
gillian.gatenby@nhs.net
Meena Balasubramanian
meena.balasubramanian@nhs.net
Sheffield Children's NHS Foundation Trust
Interventions
  • Drug: dexamethasone oral — The interventions are Dexamethasone, 0.3mg/kg versus 0.6 mg/kg
Study Locations (1 sites)
Sheffield Children's NHS Foundation Trust, Sheffield, S10 2TH United Kingdom
Eligibility Criteria
Inclusion Criteria: * Children aged 4-15 years (inclusive) presenting to the ED with an asthma exacerbation, where oral steroids are recommended by Trust/National guidelines. * Children whose parents/carers do not speak English will also be eligible provided they speak one of the common languages where an interpreter and Information Sheets are available (Slovakian, Arabic and Urdu). Exclusion Criteria: * Children who have been treated with oral or IV steroids in the last 2 weeks. * Hypersensitivity to the study drug. * Children who have concomitant stridor. * First episode of wheezing (not previously diagnosed as asthma). * Children with known difficult asthma who receive longer courses of steroids as standard. * Life threatening episode of asthma. * Children with other conditions that require them to have steroids when unwell. * Children who are involved in current research or have recently been involved in research prior to recruitment
Conditions HER2 + Breast Cancer
Phase PHASE2
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Patients with Stage II-III HER2-positive breast cancer will receive three cycles of treatment with Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab, followed by imaging assessment. If clinical complete response (cCR) or radiological complete response/near radiological complete response (rCR/near rCR) is achieved, they will continue to receive an additional three cycles of treatment with Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab, followed by surgery. If cCR/rCR or near rCR is not achieved, the treatment will be switched to the THPy regimen (paclitaxel-based regimen + Trastuzumab + Pyrotinib) for three cycles.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Trastuzumab Deruxtecan — 4.8mg/kg, d1, q3w
  • Drug: Pertuzumab — 840mg on cycle1, 420mg on following cycles, d1, q3w
  • Drug: Taxane Chemotherapy — Nab-paclitaxel 100 mg per square meter, d1,d8,d15 q3w Or Paclitaxel 80mg per square meter, d1,d8,d15 q3w Or Docetaxel 100mg per square meter, d1 q3w
  • Drug: Trastuzumab (or biosimilar) — Trastuzumab 8mg/kg (loading dose) or 6mg/kg on following cycles, d1, q3w
  • Drug: Pyrotinib 320mg — 320mg qd

Primary Outcomes

  • pCR (after neoadjuvant treatment, at surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-02-02
Completion: 2032-09-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shanghai Jiao Tong University School of Medicine
Collaborators: Jiangsu HengRui Medicine Co., Ltd.
Contact Information
Study Contact:
Xiaosong Chen, Ph.D
+86-21-64370045-602102
chenxiaosong0156@hotmail.com
Jiayi Wu, Ph.D
+86-21-64370045-602101
pinkscorpio@163.com
Xiaosong Chen
+86-21-64370045-602102
xiaosongchen0156@hotmail.com
Shanghai Jiaotong University School of Medicine affiliated Ruijin Hospital
Interventions
  • Drug: Trastuzumab Deruxtecan — 4.8mg/kg, d1, q3w
  • Drug: Pertuzumab — 840mg on cycle1, 420mg on following cycles, d1, q3w
  • Drug: Taxane Chemotherapy — Nab-paclitaxel 100 mg per square meter, d1,d8,d15 q3w Or Paclitaxel 80mg per square meter, d1,d8,d15 q3w Or Docetaxel 100mg per square meter, d1 q3w
  • Drug: Trastuzumab (or biosimilar) — Trastuzumab 8mg/kg (loading dose) or 6mg/kg on following cycles, d1, q3w
  • Drug: Pyrotinib 320mg — 320mg qd
Study Locations (1 sites)
Shanghai Jiaotong University School of Medicine affiliated Ruijin Hospital, Shanghai, Shanghai Municipality China
Eligibility Criteria
Inclusion Criteria: * Age and Gender: Female patients aged ≥18 years and ≤70 years. Histological Confirmation: Patients must have histologically confirmed invasive breast cancer and must not have received any prior systemic anti-tumor therapy for breast cancer. * HER2 Positivity: Histologically confirmed HER2 receptor positivity, following the 2018 ASCO-CAP HER2 positivity judgment guidelines. Confirmed by pathology laboratory with immunohistochemistry (IHC) score of 3+, or 2+ with positive in situ hybridization (ISH) test (ISH amplification rate ≥2.0). * Tumor Stage: Patients must have tumor staging conforming to the Stage II-III breast cancer criteria according to the eighth edition of the AJCC breast cancer TNM staging system (T1\~T4, N1\~N3, M0). * Measurable Target Lesion: At least one measurable target lesion according to RECIST V1.1. * ECOG Performance Status: ECOG functional status score of 0\~1. * Organ Function: Adequate organ function levels, with the following requirements (no blood transfusion or use of leukocyte or platelet elevation drugs within 2 weeks prior to screening): * Hematology: Absolute neutrophil count (ANC) \> 1.5 × 109/L; Platelet count (PLT) \> 75 × 109/L; Hemoglobin (Hb) \> 90 g/L. * Blood Chemistry: Total bilirubin (TBIL) \< 1.5 × ULN; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 1.5 × ULN; Alkaline phosphatase \< 2.5 × ULN; Blood urea nitrogen/urea (BUN/UREA) and creatinine (Cr) \< 1.5 × ULN. * Cardiac Ultrasound: Left ventricular ejection fraction (LVEF) ≥ 55%. * 12-Lead ECG: Fridericia's method corrected QT interval (QTcF) \< 470 msec. * Reproductive Status: For premenopausal women with potential fertility, a pregnancy test must be performed within 7 days before treatment initiation, with negative serum/urine pregnancy results. * Patients must not be lactating and must use adequate barrier contraception throughout the treatment cycle and for 6 months after treatment completion. Voluntary Participation: Voluntary participation in the study with signed informed consent, good compliance, and willingness to cooperate with visit schedules and research-related procedures. Exclusion Criteria: * Stage IV Breast Cancer: Patients with Stage IV breast cancer. Inflammatory Breast Cancer: Patients with inflammatory breast cancer. Prior Malignancy Treatment: Patients who have received prior anti-tumor therapy or radiotherapy for any malignancy, or have concurrent other malignancies, excluding cured cervical intraepithelial neoplasia, basal cell carcinoma, or squamous cell carcinoma. * Concurrent Anti-Tumor Therapy: Patients currently participating in other clinical trials involving anti-tumor therapy, including but not limited to chemotherapy, endocrine therapy, biological therapy, bone modification therapy, or immune checkpoint inhibitor therapy. * Recent Surgery: Patients who have undergone major surgery unrelated to breast cancer within 4 weeks prior to the first dose of the study drug, or have not fully recovered from such surgery. * Serious Cardiac Disease: Patients with serious cardiac conditions, including but not limited to: * History of heart failure or systolic dysfunction (LVEF \< 50%). Uncontrolled high-risk arrhythmia, such as atrial tachycardia, resting heart rate \> 100 bpm, significant ventricular arrhythmia, or advanced atrioventricular block (i.e., Mobitz II second-degree or third-degree atrioventricular block). * Angina pectoris requiring medication. * Clinically significant heart valve disease. * ECG showing transmural myocardial infarction. * Uncontrolled hypertension (after medication, systolic blood pressure \> 180 mmHg and/or diastolic blood pressure \> 100 mmHg). * Uncontrolled Active Infection: Patients with uncontrolled active infection requiring treatment, or with a history of immunodeficiency, including HIV positivity, other acquired or congenital immunodeficiency diseases, or a history of organ transplantation. * Allergy to Study Drugs: Patients with a known history of allergy to any component of the study drugs. * Pregnant or Lactating Women: Pregnant or lactating women, women of childbearing potential with positive baseline pregnancy test, or those unwilling to use effective contraception during the trial period and for 6 months after the last dose of the study drug. * Interstitial Lung Disease: Patients with known or suspected interstitial lung disease; those with other severe pulmonary diseases that may interfere with drug-related pulmonary toxicity detection or management within 3 months prior to the first dose, including but not limited to idiopathic pulmonary fibrosis, organizing pneumonia/obliterative bronchiolitis, pulmonary embolism, severe asthma, severe chronic obstructive pulmonary disease (COPD), restrictive/obstructive lung disease, or any pulmonary autoimmune or inflammatory disease such as rheumatoid arthritis, Sjögren's syndrome, or sarcoidosis; or those with a history of total pneumonectomy. * Severe Concomitant Diseases: Patients with severe concomitant diseases or other conditions that may interfere with the planned treatment, or those deemed unsuitable for the study by the investigator for any other reason.
Conditions Depression and Anxiety Symptom
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to investigate the effects of guided internet-based cogitive behavioral therapy (ICBT) on psychological symptoms related to economy. In this pilot study, the investigators investigate participants' psychological symptoms before and after, and one and two years after, they have received eight weeks of therapist guided ICBT.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Internet-based cognitive behavioral therapy — The treatment consists of eight treatment modules that the participants receive, one module each week in eight weeks. The modules consists of texts, pictures and interactive exercises. The participants also get weekly guidance by a therapist and they can contact their therapist during the week if needed.

Primary Outcomes

  • InCharge Financial Distress/Financial Well-Being Scale (Participants will complete this questionnaire at baseline, immediately after treatment, one year after treatment, and two years after treatment completion.)
  • Mongomery-Asberg Depression Rating Scale - Självrapportering (Participants will complete this questionnaire at baseline, immediately after treatment, one year after treatment, and two years after treatment completion.)
  • Generalized Anxiety Scale-7 item scale (Participants will complete this questionnaire at baseline, immediately after treatment, one year after treatment, and two years after treatment completion.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-14
Completion: 2028-05-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Linkoeping University
Contact Information
Study Contact:
Gerhard Andersson, PhD
+46-13285840
gerhard.andersson@liu.se
Victoria Aminoff
+4613281948
victoria.aminoff@liu.se
Gerhard Andersson, PhD
+46-13285840
gerhard.andersson@liu.se
Department of Behavioral Sciences and Learning
Interventions
  • Behavioral: Internet-based cognitive behavioral therapy — The treatment consists of eight treatment modules that the participants receive, one module each week in eight weeks. The modules consists of texts, pictures and interactive exercises. The participants also get weekly guidance by a therapist and they can contact their therapist during the week if needed.
Study Locations (1 sites)
Department of Behavioral Sciences and Learning, Linköping, Östergötland County 58183 Sweden
Eligibility Criteria
Inclusion Criteria: * Experience mild to moderate psychological symptoms or problems related to economy * 18 years or older * Ability to speak, read and write in Swedish * Have access to the internet and a smartphone, computer or other device Exclusion Criteria: * Severe psychiatric or somatic illness that makes participation harder or impossible * Ongoing addiction * Acute suicidality * Other ongoing psychological treatment * Recent (within the latest month) changes in the dose of psychotropic medication or planned change of dose during the treatment weeks
Conditions Liver Transplantation, Portal Hypertensi...
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to compare the effects of somatostatin and terlipressin on lowering portal pressure in patients with portal hypertension undergoing liver transplantation, and to investigate whether there are differences in clinical outcomes between the two drugs. The study will evaluate the decrease in portal pressure from baseline following drug administration at defined time points. It will also compare the effects of these drugs on hemodynamics, bleeding, and transfusion requirements. After baseline intraoperative direct portal pressure measurement, a bolus dose of the study drug will be administered, followed by continuous intravenous infusion intraoperatively and for 24 hours postoperatively. Direct portal pressure will be measured again 5 minutes after the bolus dose, after the portal vein anastomosis, after the hepatic artery anastomosis, and, if performed after splenic artery ligation. Hemodynamic parameters will be recorded, and the drugs will be compared in terms of their intraoperative hemodynamic effects. As elevated portal pressure is associated with increased bleeding, intraoperative blood loss and transfusion needs will also be assessed between the groups. Patients will be followed for 7 days postoperatively for clinical and laboratory outcomes.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Somatostatin — Following baseline portal pressure measurement from the portal vein (25 Gauge intracath, Bıçakçılar®) (PVP0), somatostatin (Somatex®) will be administered as a 250 mcg bolus over 2 minutes, followed by a continuous infusion at 2.5 mcg/kg/hour. Direct portal measurements will be done at the time points explained in the study description. Intraoperative ultrasound (GE Healthcare®, linear probe) will be used to record arterial and portal flow parameters. Hemodynamic data will be collected during all measurements. The study drug will be infused continuously for at least 24 hours.
  • Drug: Terlipressin — Following baseline portal pressure measurement from the portal vein (25 Gauge intracath, Bıçakçılar®) (PVP0), terlipressin (Glypressin®) will be administered as a 1 mg bolus over 2 minutes, followed by a continuous infusion at 2 mcg/kg/hour. Direct portal measurements will be done at the time points explained in the study description. Intraoperative ultrasound (GE Healthcare®, linear probe) will be used to record arterial and portal flow parameters. Hemodynamic data will be collected during all measurements. The study drug will be infused continuously for at least 24 hours, and up to 5 days if portal pressure remains elevated.

Primary Outcomes

  • Decrease in portal pressure by 20% from the baseline (Baseline (before bolus drug administration) 5 minutes after bolus drug administration Immediately after completion of the portal vein anastomosis Immediately after completion of the hepatic artery anastomosis)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-12-29
Completion: 2027-03-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Istanbul Medipol University Hospital
Principal Investigators:
  • ayşe ince (PRINCIPAL_INVESTIGATOR) - Istanbul Medipol University Medipol Mega Hospital
Contact Information
Study Contact:
ayse ince, assist prof
+905366774988
drayseince@gmail.com
pelin karaaslan, prof
+905057657550
drpelinsesli@hotmail.com
ayşe ince, assist prof
5366774988
drayseince@gmail.com
Istanbul Medipol University Medipol Mega Hospital
Interventions
  • Drug: Somatostatin — Following baseline portal pressure measurement from the portal vein (25 Gauge intracath, Bıçakçılar®) (PVP0), somatostatin (Somatex®) will be administered as a 250 mcg bolus over 2 minutes, followed by a continuous infusion at 2.5 mcg/kg/hour. Direct portal measurements will be done at the time points explained in the study description. Intraoperative ultrasound (GE Healthcare®, linear probe) will be used to record arterial and portal flow parameters. Hemodynamic data will be collected during all measurements. The study drug will be infused continuously for at least 24 hours.
  • Drug: Terlipressin — Following baseline portal pressure measurement from the portal vein (25 Gauge intracath, Bıçakçılar®) (PVP0), terlipressin (Glypressin®) will be administered as a 1 mg bolus over 2 minutes, followed by a continuous infusion at 2 mcg/kg/hour. Direct portal measurements will be done at the time points explained in the study description. Intraoperative ultrasound (GE Healthcare®, linear probe) will be used to record arterial and portal flow parameters. Hemodynamic data will be collected during all measurements. The study drug will be infused continuously for at least 24 hours, and up to 5 days if portal pressure remains elevated.
Study Locations (1 sites)
Istanbul Medipol University Medipol Mega Hospital, Istanbul, Bagcilar 34218 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: Patients scheduled for right lobe living donor liver transplantation with clinically significant portal hypertension (esophageal varices, thrombocytopenia (\<100,000), ascites, encephalopathy; Child-Turcotte-Pugh class B-C) Exclusion Criteria: * Allergy to any of the medications to be used * Portal vein thrombosis * Being treated with terlipressin with a diagnosis of hepatorenal syndrome * Portopulmonary hypertension * Acute on chronic liver failure * Chronic renal failure (glomerular filtration rate ≤ 30%) * Myocardial ischemia * Uncontrolled hypertension * Arrhythmia * Multiple solid organ transplantation
Conditions HR Positive/HER2 Low Breast Cancer
Phase PHASE2
Enrollment 111
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is a prospective, multi-cohort, multicenter, open-label exploratory clinical trial. The primary study objective is to evaluate the pathologic complete response (PCR) of treatment of HR+/HER2-low breast cancer with neoadjuvant therapy combined with Trastuzumab Rezetecan and Toripalimab , including the incidences and types of adverse events. The secondary endpoints include event-free survival (EFS), residual cancer burden (RCB), and objective response rate (ORR).

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Neoadjuvant therapy combined with Trastuzumab Rezetecan and Toripalimab — Trastuzumab Rezetecan administered intravenously at a dose of 4.8mg/kg every 3 weeks for a total of 24 weeks with Toripalimab intravenous infusion of 240mg. During postoperative adjuvant therapy, Toripalimab used as before till a total of 1 year.
  • Drug: Neoadjuvant Chemotherapy in Combination with Toripalimab — Epirubicin (or Liposomal Doxorubicin)+Cyclophosphamide, intravenous infusion of 100 mg/m2. Epirubicin (or 35 mg/m2 liposomal doxorubicin)+600 mg/m2 cyclophosphamide, starting from the first day of the week, for a total of 12 weeks. Paclitaxel, administered intravenously at a dose of 260 mg/m2 every 3 weeks for a total of 12 weeks. During neoadjuvant chemotherapy and postoperative adjuvant therapy, use of Toripalimab: intravenous infusion of 240 mg, once every 3 weeks, combined with preoperative neoadjuvant and postoperative adjuvant therapy for a total of 1 year.
  • Drug: Neoadjuvant Chemotherapy — Epirubicin (or Liposomal Doxorubicin)+Cyclophosphamide, intravenous infusion of 100 mg/m2. Epirubicin (or 35 mg/m2 liposomal doxorubicin)+600 mg/m2 cyclophosphamide, starting from the first day of the week, for a total of 12 weeks. Paclitaxel, administered intravenously at a dose of 260 mg/m2 every 3 weeks for a total of 12 weeks.

Primary Outcomes

  • pathologic complete response(PCR) (2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-02-01
Completion: 2031-02-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 111 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: First Affiliated Hospital of Zhejiang University
Contact Information
Study Contact:
Zhijun Dai
+86 157 0581 9132
dzj0911@126.com
Wanting Shao
+86 13777556621
shaowt111@163.com
Tong Liu
Harbin Medical University Cancer Hospital
Interventions
  • Drug: Neoadjuvant therapy combined with Trastuzumab Rezetecan and Toripalimab — Trastuzumab Rezetecan administered intravenously at a dose of 4.8mg/kg every 3 weeks for a total of 24 weeks with Toripalimab intravenous infusion of 240mg. During postoperative adjuvant therapy, Toripalimab used as before till a total of 1 year.
  • Drug: Neoadjuvant Chemotherapy in Combination with Toripalimab — Epirubicin (or Liposomal Doxorubicin)+Cyclophosphamide, intravenous infusion of 100 mg/m2. Epirubicin (or 35 mg/m2 liposomal doxorubicin)+600 mg/m2 cyclophosphamide, starting from the first day of the week, for a total of 12 weeks. Paclitaxel, administered intravenously at a dose of 260 mg/m2 every 3 weeks for a total of 12 weeks. During neoadjuvant chemotherapy and postoperative adjuvant therapy, use of Toripalimab: intravenous infusion of 240 mg, once every 3 weeks, combined with preoperative neoadjuvant and postoperative adjuvant therapy for a total of 1 year.
  • Drug: Neoadjuvant Chemotherapy — Epirubicin (or Liposomal Doxorubicin)+Cyclophosphamide, intravenous infusion of 100 mg/m2. Epirubicin (or 35 mg/m2 liposomal doxorubicin)+600 mg/m2 cyclophosphamide, starting from the first day of the week, for a total of 12 weeks. Paclitaxel, administered intravenously at a dose of 260 mg/m2 every 3 weeks for a total of 12 weeks.
Study Locations (5 sites)
Harbin Medical University Cancer Hospital, Harbin, China
The First Affiliated Hospital of Anhui Medical University, Hefei, China
Zhongshan Hospital, Fudan University, Shanghai, China
The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
The Second Affiliated Hospital of Xi'an Jiaotong University, Zhengzhou, China
Eligibility Criteria
Inclusion Criteria: 1. Female patients aged 18-70 years old; 2. ECOG score is 0-1 points; 3. Histologically or pathologically confirmed invasive breast cancer, meeting the following criteria simultaneously: Invasive breast cancer staged as T1cN1-2M0 or T2-3N0-2M0; All patients must be pathohistologically confirmed as HR-positive/HER2-low. The interpretation of ER and PR status follows the 2020 ASCO/CAP Guidelines: expression ≥1% is defined as positive, and HR positivity is confirmed if either ER or PR is positive. The interpretation of HER2 status follows the 2023 ASCO/CAP Guidelines: HER2-low is defined as HER2 1+ or 2+ with negative FISH test results. Pathological testing for PD-L1 expression: The Combined Positive Score (CPS) is the percentage of PD-L1-positive cells (including tumor cells, lymphocytes, and macrophages) among the total number of tumor cells. The PD-L1 antibody clone used for detection at our center is 22C3. No prior anti-cancer treatment. 4. Function levels of major organs must meet the required criteria 5. For female patients who have not yet reached menopause or undergone surgical sterilization: during the treatment period and in the study treatment, the final use effective contraceptive methods for at least 6 months after a single administration. 6. Voluntarily join this study, sign an informed consent form, have good compliance, and are willing to cooperate with follow-up. Exclusion Criteria: 1. Stage IV breast cancer. 2. Inflammatory breast cancer. 3. Previously received anti-tumor treatment or radiation therapy for any malignant tumor, excluding those that have been cured Malignant tumors such as cervical carcinoma in situ, basal cell carcinoma, or squamous cell carcinoma. 4. Simultaneously undergoing anti-tumor treatment in other clinical trials, including but not limited to chemotherapy and endocrine therapy. Treatment, biological therapy, bone improvement drug therapy, or immune checkpoint inhibitor therapy, etc. 5. The patient had undergone major surgical procedures unrelated to breast cancer within 4 weeks before the first administration of the study drug, or the patient has not fully recovered from such surgical procedures. 6. Serious heart disease or discomfort. 7. Uncontrolled active infections that require treatment; History of immunodeficiency, including HIV testing positive Sexual, or suffering from other acquired or congenital immunodeficiency diseases, or having a history of organ transplantation. 8. Patients with chronic active hepatitis B or active hepatitis C 9. Have received immunotherapy and experienced adverse immune events such as immune related pneumonia and myocarditis, which have been determined by researchers to potentially affect the safety of the experimental medication. 10. Individuals with a known history of allergies to the components of this medication regimen.
Conditions Hypertension
Phase Not Applicable
Enrollment 15000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a retrospective observational cohort study based on secondary use of routinely collected electronic health data. The design was selected to enable population-level characterisation of treatment patterns and clinical inertia (both diagnostic and therapeutic) in the management of hypertension across diverse settings in Brazil's public primary care system (SUS).

Design

Study type: Observational Observational model: Cohort Time perspective: Retrospective

Primary Outcomes

  • Uncontrolled blood pressure (through study completion, an average of 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-03-31
Completion: 2026-09-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 15000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AstraZeneca
Principal Investigators:
  • Julia Machline Carrion, Medical (PRINCIPAL_INVESTIGATOR) - EpHealth Soluções em Tecnologia da Informação Ltda
Contact Information
Study Contact:
AstraZeneca Clinical Study Information Center
1-877-240-9479
information.center@astrazeneca.com
Interventions
N/A
Study Locations (1 sites)
Research Site, Florianópolis, Brazil
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years at the time of Hypertension diagnosis * Hypertension diagnosis as retrieved from registered ICD codes or CIAP Codes (primary care codes) in the EMR , OR At least two blood pressure measurements ≥140/90 mmHg during the study period. The blood measurements should be consecutive and obtained within a 30 days period. * Continuous follow-up in the same municipality for at least 6 months after index measurement. * Availability of structured EMR data including clinical encounters, diagnoses, and prescriptions Exclusion Criteria: \- Patients with incomplete data or not traceable in the registration systems
Conditions Insomnia, Depressive Symptoms
Phase NA
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to evaluate the effects of sleep hygiene education on sleep quality and depression in women during menopause. Women will be randomly assigned to either an education group or a control group. The education group will receive training based on the Information-Motivation-Behavioral Skills (IMB) Model. Sleep quality and depression levels will be measured before and after the education. The results will provide insight into whether sleep hygiene education can improve sleep quality and reduce depression in menopausal women.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Sleep Hygiene Education — Education based on the IMB Model targeting sleep habits, routines, and sleep hygiene behaviors to improve sleep quality.

Primary Outcomes

  • Sleep Quality (Baseline and 10 weeks after intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-01
Completion: 2026-06-30
Eligibility
Age: 45 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ankara Yildirim Beyazıt University
Principal Investigators:
  • Ayten ARIÖZ DÜZGÜN (STUDY_DIRECTOR) - Ankara Yildirim Beyazıt University
Contact Information
Study Contact:
Busra Karagol
+90 544 574 56 95
busrakaragol22@gmail.com
Ankara Atatürk Sanatorium Training and Research Hospital
+90 544 574 56 95
busrakaragol22@gmail.com
Ankara Atatürk Sanatorium Training and Research Hospital
Aytebn ARIÖZ DÜZGÜN
Ankara Atatürk Sanatorium Training and Research Hospital
Interventions
  • Behavioral: Sleep Hygiene Education — Education based on the IMB Model targeting sleep habits, routines, and sleep hygiene behaviors to improve sleep quality.
Study Locations (1 sites)
Ankara Atatürk Sanatorium Training and Research Hospital, Ankara, Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Being in menopause * Being between 40 and 60 years of age * Having a low sleep quality score according to the Menopause-Specific Sleep Quality Scale. * Being willing to participate in the study. * Having no physical or mental disabilities that would hinder communication. * Having technology (smartphone, tablet, or computer) with internet access and the ability to participate in online training. Exclusion Criteria: * Having a history of receiving psychological support. * Having been diagnosed with a chronic psychiatric illness (previously diagnosed depression, anxiety disorder, etc.). * Having a neurological or chronic systemic illness that may affect sleep quality. * Being treated for a sleep disorder (receiving medication or psychotherapy). * Receiving hormone replacement therapy (HT). * Having received sleep hygiene training/therapy within the last 6 months.
Conditions Type 2 Diabetes Mellitus (T2DM)
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to explore whether quinoa diet can improve glycolipid metabolism and glucose fluctuations in patients with early-stage type 2 diabetes mellitus (T2DM) and observe its impact on islet β-cell function and insulin resistance in patients with early-stage T2DM (diagnosed according to the 1999 WHO criteria, disease duration \<5 years, HbA1c 6.5%-10%, no history of insulin therapy, aged 20-70 years). The main question it aims to answer is: Can quinoa diet reduce blood glucose (fasting blood glucose, postprandial blood glucose, glycosylated hemoglobin), improve lipid metabolism (cholesterol, triglycerides), and stabilize glucose fluctuations (time in range, time above range) in patients with early-stage T2DM? Does quinoa diet improve islet β-cell function (HOMA-β) and insulin resistance (HOMA-IR), and reduce the need for oral hypoglycemic medications? Comparison group: Researchers will compare the quinoa diet (QD) group (replacing traditional starchy foods with quinoa products) vs. the regular diet (RD) group (conventional diet) to see if quinoa diet demonstrates better metabolic improvement and medication reduction effects. Participants will: Be randomly assigned to the QD group or RD group. Undergo oral glucose tolerance tests (OGTTs) and continuous glucose monitoring (cGMS) at baseline and after the intervention. The QD group will consume quinoa-based foods (noodles, blended powder, cookies) as substitutes for staple foods, beverages, and snacks for 14 weeks, documenting daily intake in a record book. Both groups will receive standardized dietary and exercise education, with monthly follow-ups for food distribution and data collection.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Dietary Supplement: Quinoa-based foods — Quinoa-based foods included three varieties: quinoa noodles (80 g per bag; the ingredients included quinoa powder, red bean powder, black wheat powder, black mung bean powder, and edible salt, with quinoa powder comprising 15% of the total produced by Shandong Tangren Duoyi Biotechnology Company), blended powder (15 g per bag; the ingredients included quinoa, rye wheat, black mung beans, adzuki beans, black sesame seeds, chickpeas, konjac flour, and mogroside, with quinoa flour comprising 20% of the total produced by Shandong Tangren Duoyi Biotechnology Company), and cookies (24 g per bag; quinoa, rye, adzuki beans, black sesame seeds, vegetable oil, and salt, with quinoa comprising 20% of the total produced by Shandong Tangren Duoyi Biotechnology Company). These products serve as substitutes for the common starchy staples, soups, porridge, and snacks typically consumed by T2DM patients. This substitution did not alter patients' daily eating habits; rather, it simply replaced tradition

Primary Outcomes

  • Glucose variability (MAGE) assessed by continuous glucose monitoring (From registration to the end of the 14-week treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-01-10
Completion: 2025-12-30
Eligibility
Age: 20 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Qilu Hospital of Shandong University
Contact Information
Study Contact:
Xiao K Tang
008618560083053
tangkx_ql@hotmail.com
Xiao K Tang
0086053182166120
420247867@qq.com
Qilu Hospital of Shandong University
Interventions
  • Dietary Supplement: Quinoa-based foods — Quinoa-based foods included three varieties: quinoa noodles (80 g per bag; the ingredients included quinoa powder, red bean powder, black wheat powder, black mung bean powder, and edible salt, with quinoa powder comprising 15% of the total produced by Shandong Tangren Duoyi Biotechnology Company), blended powder (15 g per bag; the ingredients included quinoa, rye wheat, black mung beans, adzuki beans, black sesame seeds, chickpeas, konjac flour, and mogroside, with quinoa flour comprising 20% of the total produced by Shandong Tangren Duoyi Biotechnology Company), and cookies (24 g per bag; quinoa, rye, adzuki beans, black sesame seeds, vegetable oil, and salt, with quinoa comprising 20% of the total produced by Shandong Tangren Duoyi Biotechnology Company). These products serve as substitutes for the common starchy staples, soups, porridge, and snacks typically consumed by T2DM patients. This substitution did not alter patients' daily eating habits; rather, it simply replaced tradition
Study Locations (1 sites)
Qilu Hospital of Shandong University, Jinan, Shandong 250000 China
Eligibility Criteria
Inclusion Criteria: patients diagnosed according to the 1999 WHO diagnostic criteria for T2DM with a duration of less than 5 years HbA1c levels between 6.5% and 10% no history of insulin therapy age between 20 and 70 years. Exclusion Criteria: acute complications of diabetes, such as diabetic ketoacidosis severe acute or chronic conditions affecting the liver, kidneys, heart, cerebrovascular system, gastrointestinal tract, or acute infectious diseases pregnancy or plans for pregnancy soon allergies to quinoa or bean products participation in other dietary interventions or drug clinical trials within the past three months gastrointestinal diseases within two weeks prior to enrolment.
Conditions Fibromyalgia (FM)
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate the effectiveness and medium-term maintenance of a structured dog-assisted therapy (DAT) protocol, "Entre Patas e Afetos" (Between Paws and Affections), in reducing pain, anxiety and depressive symptoms and in improving functional status and quality of life in Portuguese patients with fibromyalgia (FM) followed at ULS Alto Ave, with systematic outcome assessment in the immediate post intervention phase (T2), 6-month follow-up (T3) and 12-month follow-up (T4).

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Behavioral: Dog Assisted Therapy (DAT - "Between Paws and Affections") — Dog Assisted Therapy (DAT - "Between Paws and Affections") - Intervention group that will receive a total of 10 group sessions at the Psychiatry Day Hospital of ULS Alto Ave, organized into 4 weekly structured sessions (combining psychoeducation on fibromyalgia and chronic pain, functional training and self care, lifestyle counseling and guided relaxation, all mediated by trained therapy dogs and a professional dog handler), followed by 6 monthly guided relaxation "booster" sessions with the dogs.
  • Behavioral: Behavioral: Psychoeducation and Relaxation without Dogs (Control) — Control group that will receive the same 10 session program, with structure, duration and content identical to the DAT arm (4 weekly structured psychoeducation and functional/self care sessions plus 6 monthly guided relaxation "booster" sessions), but delivered entirely without dogs.

Primary Outcomes

  • Pain intensity (maximum and average) and pain interference (13 months - From 1 month after enrollment to the end of treatment at 12 months after the first month)
  • Fibromyalgia impact and functional status (13 months - From 1 month after enrollment to the end of treatment at 12 months after the first month)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-22
Completion: 2029-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Minho
Collaborators: Unidade Local de Saúde do Alto Ave, EPE
Principal Investigators:
  • Armando Almeida, Associate Professor (STUDY_CHAIR) - School of Medicine, University of Minho
  • Filipa Martins-Alves, Psychiatric Hospital Assistant (PRINCIPAL_INVESTIGATOR) - Psychiatry Department, Unidade Local de Saúde (ULS) Alto Ave
Contact Information
Study Contact:
Armando Almeida, Associate Professor
+351 936615717
aalmeida@med.uminho.pt
Filipa Martins-Alves, Psychiatric Hospital Assistant
+351 964770140
id12083@alunos.uminho.pt
Filipa Martins-Alves, Psychiatric Hospital Assistant
+351-964770140
id12083@alunos.uminho.pt
Unidade Local de Saúde (ULS) Alto Ave
Interventions
  • Behavioral: Behavioral: Dog Assisted Therapy (DAT - "Between Paws and Affections") — Dog Assisted Therapy (DAT - "Between Paws and Affections") - Intervention group that will receive a total of 10 group sessions at the Psychiatry Day Hospital of ULS Alto Ave, organized into 4 weekly structured sessions (combining psychoeducation on fibromyalgia and chronic pain, functional training and self care, lifestyle counseling and guided relaxation, all mediated by trained therapy dogs and a professional dog handler), followed by 6 monthly guided relaxation "booster" sessions with the dogs.
  • Behavioral: Behavioral: Psychoeducation and Relaxation without Dogs (Control) — Control group that will receive the same 10 session program, with structure, duration and content identical to the DAT arm (4 weekly structured psychoeducation and functional/self care sessions plus 6 monthly guided relaxation "booster" sessions), but delivered entirely without dogs.
Study Locations (1 sites)
Unidade Local de Saúde (ULS) Alto Ave, Guimarães, 4835-044 Portugal
Eligibility Criteria
Inclusion Criteria: * Age 18 years or older * Confirmed diagnosis of fibromyalgia * Being followed at ULS Alto Ave by the Multidisciplinary Pain Unit, Internal Medicine (Auto immune diseases), Physical and Rehabilitation Medicine or Neurology * Ability to read and write Portuguese and to understand the study procedures * Willingness and ability to participate voluntarily in the 10 session program and all scheduled assessments (T1-T4) * Provision of written informed consent Exclusion Criteria: * Allergy to dogs or marked fear of dogs * History of aggression towards animals * History of oncological disease * Concomitant systemic or rheumatologic disease that may confound pain and functional assessment * Decompensated psychiatric disorder or severe cognitive impairment that may compromise comprehension of the protocol or adherence to the intervention * Refusal to participate or withdrawal of consent at any point
Conditions Pregnancy, Blood Pressure Measurement in...
Phase NA
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Accurate blood pressure measurement is essential during pregnancy, as blood pressure readings guide clinical decisions related to the diagnosis and management of hypertensive disorders of pregnancy. Clinical guidelines recommend measuring blood pressure with the arm supported at heart level; however, in routine practice, blood pressure is often measured with the arm in non-standard positions. This study aims to evaluate how different arm positions affect blood pressure measurements in pregnant women. Pregnant women attending a high-risk pregnancy clinic will undergo blood pressure measurements with the arm placed in several commonly used positions, including supported at heart level, supported on the lap, and unsupported at the side. Each participant will have multiple measurements taken during a single clinic visit. The study is designed as a randomized crossover trial with stratification by trimester and chronic hypertension status, allowing each participant to serve as her own control. Participants will be enrolled across all three trimesters of pregnancy, and results will be analyzed separately for each trimester. The primary outcome is the difference in systolic and diastolic blood pressure measurements between arm positions. The findings of this study may help improve the accuracy of blood pressure measurement during pregnancy and inform clinical practice regarding optimal measurement techniques.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Other: Arm Supported at Heart Level — Blood pressure measurements are obtained with the arm supported at heart level while the participant is seated.
  • Other: Arm Supported on Lap — Blood pressure measurements are obtained with the arm supported on the participant's lap while seated.
  • Other: Arm Unsupported at Side — Blood pressure measurements are obtained with the arm unsupported at the participant's side while seated.

Primary Outcomes

  • Difference in Systolic and Diastolic Blood Pressure Between Arm Positions (At the study visit (single study visit on the day 1 of enrollment))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-12
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sheba Medical Center
Contact Information
Study Contact:
Michal Axelrod, MD MPH
+97235302697
michalaxelrod2805@gmail.com
Michal Axelrod, MD MPH
+97235302697
michalaxelrod2805@gmail.com
Sheba Medical Center
Michal Axelrod, MD MPH
Sheba Medical Center
Interventions
  • Other: Arm Supported at Heart Level — Blood pressure measurements are obtained with the arm supported at heart level while the participant is seated.
  • Other: Arm Supported on Lap — Blood pressure measurements are obtained with the arm supported on the participant's lap while seated.
  • Other: Arm Unsupported at Side — Blood pressure measurements are obtained with the arm unsupported at the participant's side while seated.
Study Locations (1 sites)
Sheba Medical Center, Ramat Gan, 5265217 Israel
Eligibility Criteria
Inclusion Criteria: * Pregnant women aged 18 to 55 years * Singleton or multiple viable intrauterine pregnancy * Gestational age corresponding to first, second, or third trimester at the time of enrollment * Ability to sit upright comfortably for the duration of blood pressure measurements * Ability to understand the study procedures and provide written informed consent Exclusion Criteria: * Preexisting significant cardiac disease (e.g., arrhythmias, congenital heart disease, severe valvular disease) * Chronic kidney disease defined as serum creatinine ≥1.5 mg/dL at enrollment * Significant upper limb or shoulder conditions that may affect arm positioning or blood pressure measurement (e.g., lymphedema, fractures, prior surgery, arteriovenous fistula) * Neurological or musculoskeletal conditions preventing proper positioning * Severe preeclampsia, eclampsia, or other acute medical conditions requiring immediate intervention * Major fetal anomaly * Intrauterine fetal demise